AnaptysBio Plans Spin-Off of Biopharma Unit as Jemperli Royalties Surge
Event summary
- AnaptysBio plans to spin off its biopharma operations into a new public company, First Tracks Biotherapeutics, by Q2 2026.
- GSK's Jemperli achieved $343 million in Q4 2025 sales, implying a $1.4 billion annualized run rate.
- AnaptysBio expects to receive over $390 million in annualized Jemperli royalties by 2029.
- Phase 1b trials for ANB033 in celiac disease and eosinophilic esophagitis are ongoing.
The big picture
AnaptysBio's strategic move to separate its royalty-generating assets from its biopharma development operations reflects a broader trend in the biotech industry to unlock value through focused, independent entities. The strong performance of Jemperli underscores the potential of royalty-based revenue models, while the spin-off aims to create two distinct investment opportunities. The success of this strategy will hinge on the execution of the spin-off and the continued commercial success of Jemperli.
What we're watching
- Spin-Off Execution
- The pace at which AnaptysBio completes the spin-off of First Tracks Biotherapeutics will determine the market's reaction and the new entity's operational independence.
- Jemperli Performance
- Whether GSK can sustain the rapid growth of Jemperli to meet its peak sales guidance of over $2.7 billion by 2029 will be critical for AnaptysBio's royalty income.
- Clinical Trial Results
- The outcomes of Phase 1b trials for ANB033 in celiac disease and eosinophilic esophagitis will shape the future development and commercial potential of this asset.
Related topics